TY - JOUR
T1 - Focus on bladder cancer
AU - Dinney, Colin P.N.
AU - McConkey, David J.
AU - Millikan, Randall E.
AU - Wu, Xifeng
AU - Bar-Eli, Menashe
AU - Adam, Liana
AU - Kamat, Ashish M.
AU - Siefker-Radtke, Arlene O.
AU - Tuziak, Tomasz
AU - Sabichi, Anita L.
AU - Grossman, H. Barton
AU - Benedict, William F.
AU - Czerniak, Bogdan
N1 - Funding Information:
Supported by NIH Specialized Programs of Research Excellence Grant in Genitourinary Cancer CA91846, and National Cancer Institute Grants CA16672, CA066723, and CA85078.
PY - 2004/8
Y1 - 2004/8
N2 - Urothelial cancer is common and has ample lethal potential. However, most patients present before the disease is clinically beyond the bladder, and tools to interrogate the biologic potential of the urothelium would be expected to produce significant advances in the management of this disease. Likewise, the combination of available chemotherapy with surgery clearly results in an improved cure fraction for patients with locally advanced disease. Thus, significant improvements in overall mortality could be expected from better patient selection for systemic therapy and incremental advances in the activity of systemic therapy. To this end, the multichannel characterization of genomic and proteomic features of various clinical phenotypes, including benefit from existing therapies, dominates current research directions. In addition, the ready availability of the urothelium should provide an extremely valuable clinical research tool to investigate minimal residual disease, gene therapy, and other novel clinical directions that will be of substantial interest from the perspective of epithelial cancers generally.
AB - Urothelial cancer is common and has ample lethal potential. However, most patients present before the disease is clinically beyond the bladder, and tools to interrogate the biologic potential of the urothelium would be expected to produce significant advances in the management of this disease. Likewise, the combination of available chemotherapy with surgery clearly results in an improved cure fraction for patients with locally advanced disease. Thus, significant improvements in overall mortality could be expected from better patient selection for systemic therapy and incremental advances in the activity of systemic therapy. To this end, the multichannel characterization of genomic and proteomic features of various clinical phenotypes, including benefit from existing therapies, dominates current research directions. In addition, the ready availability of the urothelium should provide an extremely valuable clinical research tool to investigate minimal residual disease, gene therapy, and other novel clinical directions that will be of substantial interest from the perspective of epithelial cancers generally.
UR - http://www.scopus.com/inward/record.url?scp=5144224183&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=5144224183&partnerID=8YFLogxK
U2 - 10.1016/j.ccr.2004.08.002
DO - 10.1016/j.ccr.2004.08.002
M3 - Review article
C2 - 15324694
AN - SCOPUS:5144224183
SN - 1535-6108
VL - 6
SP - 111
EP - 116
JO - Cancer cell
JF - Cancer cell
IS - 2
ER -